financetom
Business
financetom
/
Business
/
Broadcom's Fiscal 2025 Outlook Adjusted on Seasonal, AI-Related Factors, BofA Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Broadcom's Fiscal 2025 Outlook Adjusted on Seasonal, AI-Related Factors, BofA Says
Nov 7, 2024 9:20 PM

11:45 AM EST, 11/05/2024 (MT Newswires) -- Broadcom's ( AVGO ) fiscal year 2025 outlook was lowered due to various factors, including seasonal slowdowns, adjustments in Google's Tensor Processing Unit timelines, and potential changes in Apple's ( AAPL ) Wi-Fi component needs, BofA Securities said in an earnings preview emailed Tuesday.

The firm now expects fiscal 2025 sales of $59.3 billion and earnings per share of $6.

Broadcom's ( AVGO ) move to quarterly guidance instead of annual may amplify the focus on potential fluctuations in both AI-related and non-AI seasonal sales, according to the firm.

BofA said it expects Broadcom's ( AVGO ) AI revenue to grow as a percentage of sales from about 23% to 24% to over 30% by fiscal year 2026 as revenue from custom AI and networking products is expected to increase significantly.

The firm expects Broadcom ( AVGO ) to increase its dividend by about 14% in fiscal 2025 to $2.40 per share.

BofA reiterated its buy rating on Broadcom's ( AVGO ) stock and kept the price objective at $215.

Shares of the company were up 2.3% in recent trading.

Price: 172.46, Change: +3.91, Percent Change: +2.32

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved